Comments by "LW1zFog" (@lw1zfog) on "COVID-19: One in 60 people in England have coronavirus" video.

  1. 27 August 2021 As of 15 July, Public Health England’s modelling group, with the MRC Biostats Unit, estimated that overall infection mortality rate is approximately 0.096%
    40
  2. 27 August 2021 As of 15 July, Public Health England’s modelling group, with the MRC Biostats Unit, estimated that overall infection mortality rate is approximately 0.096%.
    5
  3.  @Heaney5551  derp
    2
  4. 27 August 2021 As of 15 July, Public Health England’s modelling group, with the MRC Biostats Unit, estimated that overall infection mortality rate is approximately 0.096%.
    1
  5. CDC announcement, July 2021 - “After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.”
    1
  6. THIS IS NOT A DRILL.
    1
  7. CDC announcement, July 2021 - “After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.”
    1
  8. CDC announcement, July 2021 - “After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.”
    1